Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630838 · ClinicalTrials.gov registry record · Phase 2
Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)
A Phase 2 study of Hirschsprung Disease, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 2
- Study locations
NCT00630838: Completed Phase 2 study of Hirschsprung Disease, sponsored by University of Michigan.
NCT00630838 is a Phase 2 study of Hirschsprung Disease that has completed, run by University of Michigan. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00630838, a Phase 2 study of Hirschsprung Disease, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 2
- Study locations
Study Summary
Prospective, randomized, controlled trial to test if post-operative administration of probiotics in HD patients will lead to a reduction in the occurrence of HAEC.
Primary Outcome
The primary outcome measure is reporting the number of participants diagnosed with Hirschsprung-associated enterocolitis (HAEC) after pullthrough procedure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VSL#3
Study Locations (2)
Michigan
- C.S. Mott Children's Hospital - Ann Arbor
New York
- Children's Hospital of Buffalo - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00630838 record still lists
NCT00630838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Hirschsprung Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00630838 reports a single indexed study location in Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT00630838 about?
NCT00630838 is a clinical study titled "Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)". Prospective, randomized, controlled trial to test if post-operative administration of probiotics in HD patients will lead to a reduction in the occurrence of HAEC.
What is the current status of trial NCT00630838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2006-09. Estimated completion is 2010-09.
What conditions does trial NCT00630838 study?
This clinical trial studies the following conditions: Hirschsprung Disease.
What interventions are being tested in trial NCT00630838?
The interventions under investigation include: Placebo (DRUG), VSL#3 (DRUG).
Who is sponsoring clinical trial NCT00630838?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00630838 being conducted?
This trial has 2 study locations across Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hirschsprung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00630838's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia